VivoSeq
Neurology

Alzheimer Disease

158

Pipeline Programs↗

34

Active Trials↗

61

Companies Involved↗

Alzheimer disease is a highly competitive landscape with 158 programs across 61 companies. The most active players are Acta Pharmaceuticals, Inc, Gynecologic Oncology Group, Biogen. 63 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

47/100

Mech. Concentration

4/100

Completion Rate

76/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Acta Pharmaceuticals, Inc

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1Biogen logo

Biogen

2 programs

Phase 1Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 2L

Lighthouse Pharmaceuticals, Inc.

2 programs

Phase 2E

Eastern Cooperative Oncology Group

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

135 of 153 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody85%Protein / enzyme64%Peptide21%Vaccine1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 153 classified programs, each share of the total. Modality classified for 93% of 172 pipeline programs.

Analysis

Trial Status

81

clinical trials

Completed34 · 42%
Recruiting23 · 28%
Terminated10 · 12%
Not yet recruiting5 · 6%
Active, not recruiting4 · 5%
Unknown status2 · 2%
Other3 · 4%

Clinical Trials

Trial Activity

81 trials

Daridorexant for Alzheimer Disease Prevention
Recruiting·—·Phase 2·NCT07213349·240 enrolled
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
Recruiting·WWashington University School of Medicine·N/A·NCT06439992·60 enrolled
Memory Deterioration in Alzheimer Disease
Recruiting·NNorwegian University of Science and Technology·N/A·NCT07118137·30 enrolled
Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers
Recruiting·WWashington University School of Medicine·Phase 2·NCT06274528·201 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07011732·426 enrolled
NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in Hong Kong
Recruiting·Hong Kong University of Science and Technology·N/A·NCT07347574·2,500 enrolled
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Preclinical·NCT05806697·240 enrolled
An Annual Dosing Study of Donanemab in Participants Who Completed Donanemab Study AACM
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07602582·550 enrolled
Construction of a Lecanemab Therapeutic Efficacy Evaluation System Based on Mesoporous Gold Electrode Surface-enhanced Electrochemiluminescence for Monitoring Dynamic Changes of Alzheimer's Disease Plasma Biomarkers
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Approved·NCT07688460·100 enrolled
A Study of Donanemab Versus Placebo in Chinese Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07571161·140 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Recruiting·KKaruna Therapeutics·Phase 3·NCT06585787·406 enrolled
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT07142954·3,400 enrolled
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
Recruiting·CColumbia University·Phase 2·NCT04576793·100 enrolled
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06937229·650 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06947941·325 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)